The DOI matches its Crossref record.
Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells.
Open accessAbstract
To evaluate the feasibility of using a replication-deficient recombinant adenovirus to transfer human genes to the human endothelium, human umbilical vein endothelial cells were infected in vitro with adenovirus vectors containing the lacZ gene or a human alpha 1-antitrypsin (alpha 1AT) cDNA. After in vitro infection with the lacZ adenovirus vector, cultured endothelial cells expressed beta-galactosidase. In parallel studies with the alpha 1AT adenovirus vector, infected cells expressed human alpha 1AT transcripts, as evidenced by in situ hybridization and Northern analysis, and de novo synthesized and secreted glycosylated, functional alpha 1AT within 6 hr of infection, as shown by [35S]methionine labeling and immunoprecipitation. Quantification of the culture supernatants demonstrated 0.3-0.6 micrograms of human alpha 1AT secreted per 10(6) cells in 24 hr, for at least 14 days after adenovirus vector infection. To demonstrate the feasibility of direct transfer of genes into endothelial cells in human blood vessels, lacZ or alpha 1AT adenovirus vectors were placed in the lumen of intact human umbilical veins ex vivo. Histologic evaluation of the veins after 24 hr demonstrated transfer and expression of the lacZ gene specifically to the endothelium. alpha 1AT adenovirus infection resulted both in expression of alpha 1AT transcripts in the endothelium and in de novo synthesis and secretion of alpha 1AT. Quantification of alpha 1AT in the vein perfusates showed average levels of 13 micrograms/ml after 24 hr. These observations strongly support the feasibility of in vivo human gene transfer to the endothelium mediated by replication-deficient adenovirus vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gönczöl, E., & Wilson, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4407 · Cited by 1,575
Poly(ethylenimine) and its role in gene delivery
Godbey, W. T., Wu, K. K., & Mikos, A. G. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00090-5 · Cited by 1,199
Transfer of Genes to Humans: Early Lessons and Obstacles to Success
Crystal, R. G. (1995) · Science · doi:10.1126/science.270.5235.404 · Cited by 1,000
Self-citationGodbey, W. T., Wu, K. K., & Mikos, A. G. (1999) · Journal of Biomedical Materials Research · doi:10.1002/(sici)1097-4636(19990605)45:3<268::aid-jbm15>3.0.co;2-q · Cited by 825
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Fallaux, F. J., Kranenburg, O., Cramer, S. J., Houweling, A., van Ormondt, H., Hoeben, R. C., & van der Eb, A. J. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.2-215 · Cited by 512
Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury
Ohno, T., Gordon, D., San, H., Pompili, V. J., Imperiale, M. J., Nabel, G. J., & Nabel, E. G. (1994) · Science · doi:10.1126/science.8047883 · Cited by 433
Gene therapy: adenovirus vectors
Kozarsky, K. F., & Wilson, J. M. (1993) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(93)90126-a · Cited by 419
Bajocchi, G., Feldman, S. H., Crystal, R. G., & Mastrangeli, A. (1993) · Nature Genetics · doi:10.1038/ng0393-229 · Cited by 378
Self-citationNovel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
“An Ad vector was used for the first time in 1992 to treat two genetic disorders; alpha-1 antitrypsin deficiency (Lemarchand et al., 1992) and cystic fibrosis (Rosenfeld et al.”
Wickham, T. J., Roelvink, P. W., Brough, D. E., & Kovesdi, I. (1996) · Nature Biotechnology · doi:10.1038/nbt1196-1570 · Cited by 326
Wickham, T. J., Segal, D. M., Roelvink, P. W., Carrion, M. E., Lizonova, A., Lee, G. M., & Kovesdi, I. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.6831-6838.1996 · Cited by 288
Lung Overexpression of the Vascular Endothelial Growth Factor Gene Induces Pulmonary Edema
Kaner, R. J., Ladetto, J. V., Singh, R., Fukuda, N., Matthay, M. A., & Crystal, R. G. (2000) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.22.6.3779 · Cited by 277
Self-citationLemarchand, P., Jones, M., Yamada, I., & Crystal, R. G. (1993) · Circulation Research · doi:10.1161/01.res.72.5.1132 · Cited by 257
Self-citationKienlen-Campard, P., Miolet, S., Tasiaux, B., & Octave, J.-N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200887200 · Cited by 187
The Promise of Gene Therapy For The Treatment of α-1 Antitrypsin Deficiency
Cruz, P. E., Mueller, C., & Flotte, T. R. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.9.1191 · Cited by 10
Metadata
- Authors
- Lemarchand, P., Jaffe, H. A., Danel, C., Cid, M. C., Kleinman, H. K., Stratford-Perricaudet, L. D., Perricaudet, M., Pavirani, A., Lecocq, J. P., & Crystal, R. G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-07-15
- Volume
- 89
- Issue
- 14
- Pages
- 6482-6486
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1963728714
- Cited by
- 176
- References
- 0
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.